Table 2.
Patients experiencing adverse events that possibly related to study drugs.
| System organ class-preferred term | Number of patients (n = 16) | Number of times | |||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Total | ||
| All adverse events | 16 (4.1%) | ||||
| Infections and infestations | 1 (0.3%) | ||||
| Papulopustular rash | 1 (0.3%) | 1 | 0 | 0 | 1 |
| Investigations | 16 (4.1%) | ||||
| ALT increased | 16 (4.1%) | 9 | 5 | 7 | 21 |
| AST increased | 15 (3.9%) | 9 | 3 | 4 | 16 |
| GGT increased | 5 (1.3%) | 2 | 3 | 1 | 6 |
| ALP increased | 2 (0.5%) | 2 | 0 | 0 | 2 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; ALP, blood alkaline phosphatase